Supriya Lifescience Ltd. News and Updates

Name: Latest research reports of Supriya Lifescience Ltd. authored by KRChoksey and published by - Trendlyne research reports.
Item: Supriya Lifescience Ltd.
Rating: 5
Author: KRChoksey

Keep track of all breaking news on Supriya Lifescience Ltd. from all sources in a single place.

Load latest

Supriya Lifescience Ltd.

08 Nov 2023

661.40

5.15%

Supriya Lifescience Results Earnings Call for Q2FY24

Conference Call with Supriya Lifescience Management and Analysts on Q2FY24 Performance and Outlook. Listen to the full earnings transcript.

audio

Supriya Lifescience Ltd.

24 Oct 2023

661.40

5.15%

Supriya Lifescience and KIIT collaborate on oral cancer detection kit

Business Line

Initiative marks portfolio-diversification for the Mumbai-based API-maker

Supriya Lifescience Ltd.'s price crossed above 200Day SMA today

Supriya Lifescience Ltd.

04 Aug 2023

661.40

5.15%

to see Rapid results content

Supriya Lifescience Ltd.

03 Aug 2023

661.40

5.15%

Supriya Lifescience shares rise post tie-up with US-based Plasma Nutrition

Business Line

Supriya Lifescience partners with US-based Plasma Nutrition for ioProtein launch in India

Supriya Lifescience Ltd. is trading above its 200 day SMA of 638.8

Supriya Lifescience ties up with US-based Plasma Nutrition, stock surges 7%

Business Today | 02 Aug 2023

Supriya Lifescience Ltd.

01 Jun 2023

661.40

5.15%

Buy Supriya Lifesciences; target of Rs 292: KR Choksey

Moneycontrol

KR Choksey is bullish on Supriya Lifesciences has recommended buy rating on the stock with a target price of Rs 292 in its research report dated May 31, 2023.

Number of FII/FPI investors increased from 85 to 98 in Mar 2025 qtr.

Supriya Lifescience Ltd.

31 May 2023

661.40

5.15%

Revenue recovered; challenges remain in china market

Buy: Supriya Lifescience Ltd.

Target

KRChoksey

Supriya Life Science reported a quarterly revenue growth of INR 1422.7 mn in Q4FY23, compared to INR 1051.0 mn in Q3FY23. The growth was primarily supported by strong traction in the US, Europe, and Latin America markets. Therapies such as Anti Anesthetic, Anti-Allergic, and Asthmatic played a key role in driving this growth.

Supriya Lifescience Ltd. is trading below its 30 day SMA of 703.5

Supriya Lifescience Ltd.

22 Feb 2023

661.40

5.15%

Buy Supriya Lifescience; target of Rs 278: KR Choksey

Moneycontrol

KR Choksey is bullish on Supriya Lifescience has recommended buy rating on the stock with a target price of Rs 278 in its research report dated February 17, 2023.

Supriya Lifescience Ltd. is trading below its 30 day SMA of 703.5

Supriya Lifescience Ltd.

20 Feb 2023

661.40

5.15%

Muted performance on account of multiple macro headwinds

Buy: Supriya Lifescience Ltd.

Target

KRChoksey

Supriya Life Science’s revenue has significantly declined in Q3FY23. The revenues stood at INR 1051.4mn against INR 1120.0mn in Q2FY23. The operating revenue for the 9 months was INR 3186.0mn Vs INR 3418.0mn in 9MFY22. During the quarter, the company's revenue was impacted by a slowdown in demand in a key market, namely China, as well as lower offtake for key products.

Supriya Lifescience Ltd. is trading below its 30 day SMA of 703.5

Supriya Lifescience Ltd.

14 Nov 2022

661.40

5.15%

Demand visibility to continue

Buy: Supriya Lifescience Ltd.

Recommendation Target

KRChoksey

During Q2FY23, Supriya Lifescience Ltd (SLL) reported Revenue of INR 1,120 Mn (-25.33% YoY / +10.89% QoQ). Such growth was mainly driven by strong sales from Analgesic/Anestetic segment which contributed 56% to the topline against 36% in same period last year.

Supriya Lifescience Ltd. is trading below its 30 day SMA of 703.5

Supriya Lifescience Ltd.

28 Sep 2022

661.40

5.15%

Supriya Lifescience stock tumbles as CEO resigns

Moneycontrol

The Board simultaneously approved the appointment of Rajeev Kumar Jain as Chief Executive Officer and Key Managerial Personnel of the Company, who will be joining on October 3, 2022.